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Abstract 
The ubiquitin-proteasome system plays a critical role in many diseases, making it an attractive 
biomarker and therapeutic target. However, the impact of results obtained in vitro using purified 
proteasome particles or whole cell extracts is limited by the lack of efficient methods to assess 
proteasome activity in living cells. We have engineered an internally quenched fluorogenic peptide 
with a proteasome-specific cleavage motif fused to TAT, and linked to the fluorophores DABCYL 
and EDANS. This peptide penetrates cell membranes and is rapidly cleaved by the proteasomal 
chymotrypsin-like activity, generating a quantitative fluorescent reporter of in vivo proteasome 
activity, as assessed by time-lapse or flow cytometry fluorescence analysis. This reporter is an 
innovative tool for monitoring proteasomal proteolytic activities in physiological and pathological 
conditions. 
 
 
Introduction 
The ubiquitin proteasome system (UPS) has a fundamental role in maintaining cell viability, by 
regulating the turnover of cell proteins 1-4. Its proteolytic activity provides an essential quality 
control mechanism that selectively eliminates misfolded or damaged proteins. In addition, because 
the proteasome also degrades regulatory proteins, it has an impact on virtually all biological 
processes, including regulation of gene transcription, cell cycle progression, apoptosis, development 
and 
differentiation. Finally, the proteasome generates immunogenic peptides that are presented on the 
cell 
surface, making it a key factor in self-recognition and adaptive immunity. 
Altered proteasomal activity has been implicated in many diseases, ranging from neurodegenerative 
disorders, to genetic diseases, cardiac dysfunction and autoimmune syndromes 3,5,6. Specific 
changes in 
UPS have been identified in cancer, where aberrant regulation of cell cycle proteins can lead to 
tumorigenesis 3,6,7. For this reason, the development of proteasome inhibitors as new anti-tumor 
agents 
8-10 represents a promising therapeutic strategy, as demonstrated by the success of bortezomib, a 
drug 
approved for the treatment of multiple myeloma 11. 
The efficacy of new molecules with therapeutic potential is usually evaluated using in vitro systems 
with purified components of the proteasomal system 12,13. However, results obtained by these 
methods 
may be misleading, because they measure only certain features of proteasomal degradation, and do 
not 
account for important parameters, like cell permeability, solubility, and bioavailability, as well as 
effects from interaction with other cellular components. 
To evaluate proteasomal activity in intact cells and in vivo, fluorescent proteasome substrates have 
been engineered 14-16, and have been powerful tools for investigating proteasome insufficiency and 
studying disease models in which mutant proteins overload the proteasomal capacity. However, 
these 
reporters cannot detect physiological fluctuations in the level of proteasome expression and 
functional workload, which may have profound biological implications. Moreover, accumulation of 
ubiquitin- 
GFP reporters depends not only on proteasomal activity, but also on the efficiency of their 
expression 
and ubiquitination. Finally, techniques that rely on expression of fusion proteins are not suitable for 
monitoring proteasome activity at the single cell level, or for routine diagnostics, for example in 
primary human samples. Therefore, a compelling need exists for in vivo methods for quantitating 
proteasomal activity. 
In this study, we used an innovative approach to engineer an internally quenched fluorogenic 
peptide, 
TAT-EDANS-DABCYL (TED), that is specifically recognized and hydrolyzed by β5, the main 
proteosomal subunit responsible for the chymotrypsin-like activity 17,18, the main proteasomal 
activity 
and the rate limiting activity in proteins turnover in vivo. Due to its short sequence (20 residues) 
TED 
diffuses freely into the proteasomal proteolytic core and therefore its degradation in vivo is most 
likely 
independent of preliminary ubiquitination 19. Furthermore, TED enabled the direct determination of 
proteasome efficiency in living cells, using fluorescence microscopy and flow cytometry. In fact the 
core-structure of the peptide was fused to a TAT sequence that allows the construct to efficiently 
penetrate biological membranes 20,21, thus circumventing the need for a complex macromolecule 
delivery strategy, such as viral transduction or microinjection. We added the feature of internal 
quenching by introducing the donor/acceptor pair DABCYL/EDANS 22, that allowed to easily 
follow 
fluorescence changes using the fluorescence resonance energy transfer (FRET) technique. 
Here we show that TED is a useful tool for fast and simple evaluation of proteasomal activity in 
living 
cells, and provides the possibility for in vivo monitoring of altered proteasome activity at the single-
cell 
level in patient-derived cells. 
 
 
 
 
 
Results 
Characteristics of Engineered TED Peptide. The schematic structure of TED is shown in Figure 
1. 
The strategy for designing the peptide comprised the following steps: 
1. Incubation of commercial Suc-LLVY-amc with purified 26S proteasome for 22 h caused 
complete 
degradation of the substrate, as demonstrated by HPLC/MS-MS. Figure S1 shows the proportions 
of 
the different proteolytic fragments of the peptide, with the most abundant (85%) derived from 
cleavage 
at the C-terminal site of the Tyr residue (Table S1). This showed for the first time that proteasomal 
cleavage of the prototypic substrate for chymotrypsin-like activity occurs primarily at the Tyr-amc 
bond. 
To mimic this effect, Leu-Leu-Val-Tyr (LLVY) was chosen as the “cleavage-determining motif”, 
because it is preferentially cleaved at the Tyr residue by the chymotrypsin-like activity of the 
proteasome 23,24. 
2. To further promote specific cleavage at the Tyr residue, a bulky side chain was added close to the 
Cterminus 
of the scissile motif 25,26. We chose to link the EDANS moiety to the side chain of the Glu 
residue at position 10. 
3. Residues 48-57 of the transfer domain from the TAT protein were fused to the peptide C-
terminus to 
provide cell membrane-penetration capacity 27. 
4. Lys and Arg residues promote cell membrane crossing 28, so N-terminal residues were selected to 
maximize penetration by adding three Lys residues flanking the Leu at position 5. This gave the 
peptide a net positive charge, as shown by surface charge distribution modeling (Figure S2). 
5. To minimize the possibility of N-terminal degradation, the Lys residues at positions 1, 3 and 4 
were 
in the D conformation. 
6. For internal quenching, a DABCYL group was bound to Lys at position 2, and EDANS to Glu at 
position 10. The structural model of TED was analyzed with molecular dynamic simulations 
(Figure 
S2), showing a very mobile structure, with no conformations that were more stable or preferred in 
the 
solvated environment. The fluorophore pair distance, as measured by PyMOL, was between 7 and 
30 
Å, which was lower than their Forster radius (R0 = 33 Å), the distance at which the energy transfer 
efficiency is 50% 22. 
The purity of TED was always above 98% as determined by HPLC analysis (Figure S3) and peptide 
identity was confirmed by specific analytical methods such as NMR and high resolution mass 
spectrometry analyses (Figures S4-S6 and Table S2). 
To assess if proteasomal cleavage of TED occurred specifically at the Tyr residue of LLVY, as it 
did in 
Suc-LLVY-amc, the peptide was added to HeLa cells. After 15 min, cells were collected and lysed, 
and 
the main peptide cleavage products purified and identified by reverse phase HPLC and MS. 
Representative mass spectra from HeLa cell lysates are reported in Figure 2, similar results were 
obtained for U266 and MM.1S multiple myeloma cell lines. The molecular ion at m/z 3084.48 
[M+H]+ 
that is characteristic of TED (Figure 2A) was almost negligible after cell incubation, indicating 
efficient degradation (Figure 2B). The most abundant proteolytic fragment, at m/z 1270.97, 
corresponded to the peptide obtained by cleavage of TED at the carboxyl end of the Tyr residue at 
position 8. The mass spectra also clearly showed a proteolytic fragment at m/z 1141.58, 
corresponding 
to cleavage at both the Tyr residue and the N-terminal Lys residue. No evidence of cleavage 
between 
Lys(DABCYL) residue at position 2 and D-Lys residue at position 3 was found (Figure 1). These 
results indicated that separation of the DABCYL/EDANS pair is observed only when proteolysis 
occurs at the Tyr residue, confirming that specific proteasomal cleavage caused the appearance of 
the 
fluorescent signal. 
Internalization and Cleavage of TED in Living Cells. We next evaluated TED as a reporter of 
proteasomal activity in primary hippocampal neurons, and in different tumor cell lines, specifically 
HeLa, a human cervical carcinoma line; N2a, a mouse neuroblastoma; and MM.1S and U266, two 
human multiple myeloma cell lines. Proteasomal cleavage of TED led to physical separation of the 
DABCYL/EDANS pair, abolishing intramolecular quenching, with increases in EDANS 
fluorescence 
proportional to the amount of substrate cleaved. Optical microscopy imaging using time-lapse 
recording and image analysis were performed on adherent cells, or cells in suspension after plating. 
After 5 min of incubation with 17 µM TED, time-lapse experiments showed a progressive increase 
in 
EDANS-fluorescence in most cells, reaching a maximum value within 15 min (Figure 3A and 
Figure 
S7A). The percentage of fluorescent cells varied between 38% in MM.1S cells and 87% in 
hippocampal neurons (Table 1). The half-life of the fluorescent signal was determined to be 60 min 
(data not shown). 
Changes in fluorescence signal were evaluated in parallel by FACS on U266 and MM.1S cell lines 
growing in suspension. TED cleavage in multiple myeloma cell lines was comparable to that 
observed 
by time-lapse recording, the frequency of fluorescent cells was 47.4% in U266 and 35% in MM.1S, 
indicating the versatility of this reporter. To further ascertain that fluorescence resulted from 
proteasomal activities, we used an engineered U266 human multiple myeloma cell line stably 
expressing a destabilized GFP fused to a mutated uncleavable Ub moiety (UbG76VGFP-U266 cells) 
33. 
This is an established short-lived substrate, that accumulates upon pharmacological inhibition or 
functional overload of the proteasome 14,33. No increased toxicity following exposure to proteasome 
inhibitors or TED was observed in UbG76VGFP-U266 cells 33 (data not shown). Following 
incubation of 
cells with TED, FACS analysis showed that EDANS but not UbG76VGFP fluorescence was evident; 
conversely, pretreatment with epoxomicin led to a significantly decreased EDANS fluorescence and 
GFP accumulation (Figure 3C). The inverse correlation between EDANS and GFP fluorescence 
demonstrated that TED is degraded by the proteasome. 
To determine whether the fluorescent signal was specifically due to proteasomal cleavage of TED, 
prior to peptide administration cells were incubated for 3 h with 5 µM epoxomicin, a specific and 
irreversible proteasome inhibitor 29. Epoxomicin treatment resulted in a significant decrease in 
fluorescence in HeLa, N2a, MM.1S, U266 cells and primary hippocampal neurons (Table 1; Figure 
3B and Figure S7B). Its efficacy in inhibiting TED cleavage ranged between 40 and 78%, which 
correlated 
with the sensitivity of the different cell types to the drug 30-32. In light of these observations we 
performed dose-response experiments to determine the IC50 values for epoxomicin, and two 
reversible 
and widely used proteasome inhibitors, MG-132 and bortezomib 32. As shown in Figure 4 all three 
molecules inhibited proteasomal activity in HeLa cells; epoxomicin and MG132 had a similar 
potency, 
IC50 were 13.08 µM and 6.45 µM respectively, while bortezomib showed a much greater potency 
with 
an IC50 of 141.3 nM (p=0.0016, F=14.26). 
Intracellular Localization of TED. Optical microscopy with time-lapse recording was used to 
evaluate the intracellular distribution of TED fluorescence. In primary hippocampal neurons, and in 
N2a and HeLa cell lines, we observed a prevalent nuclear distribution, as indicated by co-
localization 
of EDANS with SYTO59 nuclear staining (Figure 5 and Figure S8). Both multiple myeloma lines 
showed similar fluorescence intensity in the cytoplasm and nucleus (Figure 5 and Figure S8). 
Time-lapse recording allowed the monitoring of progressive changes in the distribution and 
intensity of 
fluorescent signals in different cell compartments. Fluorescence was initially concentrated in the 
cytoplasm of both hippocampal neurons and MM.1S cells. Signal increased progressively in the 
primary neuron culture until nuclear localization was prevalent, while a more homogeneous 
distribution between cytoplasm and nucleus was maintained in MM.1S cells (Figure S9). 
TED Detects Differential UPS Efficiency in Different Human Multiple Myeloma Cell Lines. 
We 
next tested the reporter in multiple myeloma cell lines. The MM.1S line is exquisitely 
bortezomibsensitive, 
because it expresses fewer proteasomes, which have a higher functional workload than in 
U266 cells 33. We reasoned that the reporter might discriminate between sensitive and resistant 
multiple 
myeloma cell lines by detecting idle proteasomes, so we quantified TED processing in these two 
lines. 
As shown in Figure 6, U266 cells showed a higher fluorescence intensity at each time point after 
incubation with 17 µM TED, suggesting that MM.1S cells were less efficient at cleaving the 
reporter. 
The impaired degradation of TED that we observed in MM.1S cells is consistent with the reported 
imbalance between proteasomal workload and degradative capacity in these cells 33. 
Discussion 
Proteasome activity in living cells can be assessed indirectly by a number of approaches. The 
development of fluorogenic peptides to evaluate the three main peptidase activities of the 26S 
particle, 
enables proteasomal enzymatic capacity to be determined in cell extracts 13, so allowing 
proteasomal 
complements to be compared in different cell types 33-35. However, the proteasomal complement 
may 
be adequate under normal physiological conditions, but inadequate in cells expressing 
aggregationprone 
proteotoxins, or in situations that increase the demand for proteasomal degradation 36,37. 
UPS efficiency can be inferred by measuring the half-life of proteasomal substrates. Similar 
information can be obtained by assessing the steady-state levels of Ub-conjugates or free Ub, by 
immunoblotting or autoradiography, especially in pathological conditions that challenge and 
overload 
proteasome function 38,33. However, these classical biochemical assays do not allow direct 
assessment 
of UPS efficiency in vivo. They are also demanding and time-consuming, and therefore they cannot 
be 
adopted for routine diagnostics of primary samples. 
As an alternative, fluorescent probes have been developed to measure UPS insufficiency. By 
coupling 
the degradation signal to GFP, rapid ubiquitination and proteasome-dependent degradation can be 
observed 15. These reporters efficiently detect proteasome inhibition and overload in vitro and in 
vivo, 
proving powerful means of assessing toxicity in disease models 39. However, destabilized GFPs fail 
to 
ascertain the exact step in the UPS that is impaired under pathological or stress conditions, and have 
proven inadequate for reporting on physiological fluctuations of UPS efficiency. Finally, their use 
require transient or stable transfection or transduction of the analyzed cells 40. 
More recently, a cell-based assay that employs bioluminescent synthetic peptides in a coupled-
enzyme 
format has been proposed for evaluating the three -peptidase catalytic activities 41. However, this 
assay requires weak permeabilization of the cell membrane, which may interfere with cell function. 
We attempted to overcome these limitations in UPS assessment by engineering the new peptide 
TED as 
a tool for evaluating proteasomal activity in intact living cells. TED has a TAT sequence that allows 
it 
to directly cross cell membranes. Combined with FRET, TED allows measurement of proteasomal 
activity in living cells after simple addition of the peptide to cell suspensions or culture media, 
without 
membrane permeabilization. TED abolishes the requirement for altering cell permeability and 
structure, and allows direct and quantitative evaluation of proteasomal activity by measuring the 
appearance of fluorescence. Although some fluorescence is generated independently of proteasome 
activity as an indication that experiments cannot entirely rule out a minor contribution by other 
proteases to observed fluorescence, our data show significant cleavage attributable to the 
proteasome. 
MS analysis confirmed that cleavage was specifically mediated by the chymotrypsin-like activity, at 
the Tyr residue of the prototype motif LLVY. 
In contrast to GFP-based reporters, TED is a short peptide that does not require ubiquitination for 
degradation by the proteasome 19. Real-time monitoring of TED fluorescence, for example by 
timelapse 
microscopy or repeated FACS analysis, allows kinetic evaluation of proteasomal activity in living 
cells, during basal or challenged conditions. 
The potential applications of TED in basic and translational research are manifold. In this study, we 
compared UPS efficiency in two multiple myeloma cell lines recently shown to possess different 
levels 
of proteasomes and functional workload 33. Fluorescence was higher in the multiple myeloma cell 
line 
with higher activity and lower workload, suggesting a role for TED as a reporter of proteasome 
idleness. The imbalance in proteasome load and capacity that was observed in these multiple 
myeloma 
cell lines coincided with apoptotic sensitivity to proteasome inhibitors, so TED might be employed 
to 
predict sensitivity to bortezomib in primary multiple myeloma patient-derived samples, and perhaps 
in 
other cancers. Indeed, although the proteasome inhibitor bortezomib has been successful as a 
multiple 
myeloma therapy, the molecular basis for differences in individual responsiveness remain obscure, 
and 
no predictive factor for successful treatment has been identified. More generally, TED might be 
useful 
for investigating conformational diseases marked by altered proteasomal activity, such as 
neurodegenerative disorders 5. 
Impairment of proteasome activity induces alternative proteocatabolic pathways like autophagy, 
which 
has important implications for neurodegeneration 39,42,43. The molecular sensors and networks 
linking 
UPS and autophagy are still unclear, thus TED may be valuable for monitoring the onset of 
proteasome 
impairment in disease models, for gaining mechanistic insights into the activation of autophagy. 
Another potential biotechnological application of TED is the measurement of rapidly degraded 
polypeptides (RDP). These constitute a significant proportion of total proteins, and are degraded 
soon 
after synthesis, imposing a significant load on proteasomes 44. RDP measurement relies on 
radiometabolic pulse-chase labeling and trichloracetic acid (TCA)-precipitable radioactivity 
assessment 
in the presence of proteasome inhibitors. More direct and reliable assays are needed for studying the 
role of RDP in cell function and immunity. Importantly, TED might allow direct measurement of 
RDP 
by quantifying rapid changes in fluorescence by microscopy or FACS, after pharmacological 
blockade 
of protein translation. 
The ability to monitor TED fluorescence in living cells also allows the observation of changes in the 
intracellular distribution of proteasomal activity. We found that primary neurons had a mainly 
nuclear 
distribution, and that multiple myeloma cells had equal distribution in the cytoplasm and nucleus. 
TED 
can be applied directly to living cells, excluding the possibility of artifactual uptake, or nuclear 
localization due to fixation 45. 
In conclusion, our study demonstrates that TED is an important technological development for 
investigating proteasomal activity in living cells. It should advance the analysis of the UPS in 
physiology and pathology, in both basic research and clinical applications, including diagnostics, 
new 
biomarkers and novel therapies. 
Conclusions 
The ubiquitin proteasome system (UPS) is vital for maintaining cell viability, regulating the 
turnover of 
cell proteins and providing the quality control mechanism that selectively eliminates misfolded or 
damaged proteins. Altered proteasomal activity has been implicated in many diseases, such as 
neurodegenerative disorders, genetic diseases, cardiac dysfunction and autoimmune syndromes. The 
efficacy of new molecules with therapeutic potential aimed at controlling aberrant regulation of cell 
cycle proteins is usually evaluated using in vitro systems with purified components of the 
proteasomal 
system. However, these methods may give misleading results, because they only measure limited 
features of the proteasomal degradation mechanism. To evaluate proteasome activity in intact cells 
and 
in vivo, fluorescent substrates have been engineered but they are unable to detect the physiological 
fluctuations of its expression and functional workload, which may have profound biological 
implications. Moreover, techniques that rely on expression of fusion proteins are not suitable for 
monitoring proteasomal activity at the single cell level, or for routine diagnostics, for example in 
primary human samples. We report an innovative approach to engineer an internally quenched 
fluorogenic peptide, that is specifically recognized and hydrolyzed by β5, the proteosomal subunit 
responsible for the chymotrypsin-like activity, and does not require ubiquitination to be a 
proteasomal 
substrate. This peptide permits direct determination of proteasome efficiency in living cells, using 
fluorescence microscopy and flow cytometry. Its core structure is fused to a TAT sequence that 
enables 
the construct to efficiently penetrate biological membranes so changes in the intracellular 
distribution 
of proteasomal activity can be seen as well. It can be applied directly to living cells, excluding the 
risk 
of artifactual uptake or nuclear localization due to fixation. This reporter can advance analysis of 
the 
UPS in physiology and pathology, in basic research and clinical applications, including diagnostics, 
new biomarkers and novel therapies. 
Experimental Section 
TED Synthesis and chemical characterization. TED (H-DLys-Lys(DABCYL)-DLys-DLys-Leu-
Leu- 
Val-Tyr-Gly-Glu(EDANS)-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-OH) was synthesized 
using 
solid-phase FMOC chemistry on an Applied Biosystems 433A synthesizer, and purified by reverse 
phase HPLC with a Symmetry C4 column (150 × 19 mm, 300 Å, 7 µm; Waters) on an ÄKTA 
purifier 
10 XT instrument (GE Healthcare). Identity and purity were determined both by tandem mass 
spectrometry (MS/MS) and by MALDI-time-of-flight (TOF) mass spectrometry (MS). MS/MS 
analysis have been performed with a high resolution mass spectrometer LTQ Orbitrap XL hybrid 
FTMS (Fourier Transform Mass Spectrometer) by direct infusion of TED with a Prosolia 
electrospray 
ionization (ESI) ion source. MALDI-TOF experiments were carried out with a Bruker Reflex III 
timeof- 
flight (TOF) mass spectrometer operating in the linear mode. TED purity was also checked by 
HPLC using an ÄKTA purifier 10 XT instrument (GE Healthcare) equipped with a C4 column (250 
x 
4.6 mm, 300 Å, 7 µm; Vydac) and UV/vis detector (214 and 460 nm). The retention time was 27 
min, 
in gradient solvent elution (H2O + 0.1% TFA / CH3CN + 0.08% TFA; 95:5% for 6 min, 65:35% in 
18 
min, 65:35% for 5 min, 60:40% in 8 min, 60:40% for 2 min, 0:100% in 3 min, 95:5% in 3 min, 
95:5% 
for 10 min) at the flow rate of 0.5 ml/min.TED purity was always higher than 98 %. Peptide was 
lyophilized and stored at -80 °C. Reagents were obtained from Novabiochem. 
1H-NMR and 13C-NMR characterization data of the aromatic residues of TED. 1H, 1H-1H 
DQFCOSY, 
and 1H-13C-HSQC spectra of TED dissolved in D2O were recorded at 25 °C on a Bruker 
AVANCE 400 spectrometer, operating at 9.37 T. 1H and 13C resonances, together with the coupling 
constants of aromatic residues were recorded. The large overlapping of the signals prevented the 
assignment of the aliphatic resonances. 
Determination of Suc-LLVY-amc and TED Cleavage Products. Succinyl-Leu-Leu-Val-
Tyraminomethylcoumarin 
(Suc-LLVY-amc, Bachem) degradation was performed as previously described 
46. Briefly, 200 µM Suc-LLVY-amc in 40 mM Tris, pH 7.5, 2 mM ATP, 4 mM MgCl2. was 
incubated 
for 22 h at 37 °C in the presence of 2.5 µg of 26S proteasomes, purified as reported 38. Reactions 
were 
stopped by cooling, peptides separated by filtration through a 3000 Da Microcon device (Millipore) 
and analyzed with an Agilent 6410 Triple Quadrupole LC/MS system, with a Chromolith 
FastGradient 
RP-18 endcapped 50-2 column (1.6 µm, 130 Å; Merck Chemicals). 
A solution of 17 µM TED, dissolved in water:acetonitrile (1:1), was added to cell culture medium 
and 
incubated for 15 min at 37 °C; medium was removed, cells were washed with phosphate buffered 
saline (PBS), detached and recovered by centrifugation. The pellet was resuspended in PBS, cells 
were 
lysed by freeze-thawing, centrifuged at 3000 ×g for 5 min and the supernatant used for analysis. 
Fragments from TED degradation were identified and analyzed by reverse phase HPLC and 
MALDITOF 
MS. 
Molecular Modeling. Models were built and analyzed with MacroModel (Schrodinger). The 
simulated 
system consisted of TED in a cubic box at a distance of 3.0 nm from its periodic image, with 
approximately 30,200 molecules of water. System energy was minimized with the steepest descent 
algorithm, with subsequent refinement with a conjugate gradient, followed by a 100 ps of 
equilibration 
to generate the starting point for molecular dynamics. The OPLS2001 force field was used, and all 
simulations were carried out at 298 K temperature and 1 atm pressure 47. Multiple conformations 
were 
stored at regular intervals for subsequent analysis. Electrostatic potential was calculated using the 
DelPhi program v.4 48, with finite difference solution to the nonlinear Poisson-Boltzmann equation, 
and 
visualized using PyMOL software (http://pymol.org). 
Cell Lines. Cells were cultured in DMEM (HeLa and N2a) or RPMI 1640 (U266 and MM.1S), 
both 
supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine, 100 U/ml penicillin and 100 
µg/ml 
streptomycin and maintained in humidified air at 37 °C with 5% CO2. Reagents for cell culture 
were 
obtained from Invitrogen. U266 cells stably expressing a destabilized GFP fused to a mutated 
uncleavable ubiquitin moiety (UbG76VGFP) were cultured as previously described 33. Primary 
hippocampal neuron cultures were prepared from 2-day-old rat pups as previously described 49. 
Cell Treatments. Hippocampal neurons were plated on polylysine coated 8-wells µ-Slides (1x105 
cells/well) and used after 11-13 days in culture. Confluent cell lines were detached by trypsinization, 
centrifuged, resuspended in medium without phenol red and plated as above (1-5x105 cells/well) 
and 
used after 72 h. TED in water:acetonitrile (1:1) was added to the medium at a final concentration of 
17 
µM, and cells were used immediately for optical microscopy cell imaging. Pretreatment with 
proteasome inhibitors was with 5 µM epoxomicin or 25 µM MG-132 (Novabiochem), in DMSO, at 
37 
°C for 3 h, or for 2 h for MM.1S cells, which have higher sensitivity to proteasome inhibitors 30. For 
dose-response studies, proteasome inhibitors in the range of 0.5- 20 µM for epoxomicin, 1 - 20 µM 
for 
MG-132 and 0.01 - 1 µM for bortezomib (MG-341, LC Laboratories) were added to culture 
medium 3 
h before incubation with TED. 
Flow Cytometry Analysis. After incubation with TED in the presence or absence of 5 µM 
epoxomicin, MM.1S and U266 cells were pelleted, resuspended in 1 ml of PBS and analyzed with a 
fluorescence-activated cell sorting (FACS) Vantage Instrument equipped with a Enterprise UV/488 
nm 
laser (Becton Dickinson). Fluorescence pulse was detected at 580 ± 30 nm and each flow 
cytometric 
analysis was performed on at least 20,000 cells. Data were analyzed with CellQuest (Becton 
Dickinson) software. 
Optical Microscopy and Time-lapse Recording. Adherent cells were detached by trypsinization, 
centrifuged, resuspended and plated on polylysine coated µ-Slides as described above, and grown in 
humidified air at 37 °C with 5% CO2, to 60% confluence. Cells were treated with 17 µM TED and 
immediately analyzed. For co-localization experiments, the cell nucleus was stained with SYTO59 
(Invitrogen) at a final concentration of 1 µM. Images were collected and analyzed with a CellR 
imaging 
station (Olympus) coupled to an inverted microscope (IX 81, Olympus) equipped with an incubator 
to 
maintain constant temperature (37 °C) and CO2 
(5%) values. The EDANS fluorescent signal was 
acquired with a high resolution camera (ORCA) equipped with a 340 nm excitation filter (D340xv2 
Chroma), a 400 nm dichroic mirror (400DCLP, Chroma) and an emission filter with a range of 510 
± 
40 nm (D510/40m, Chroma). Images were acquired after 15 min of incubation and 10 different 
frames 
randomly sampled for a minimum of 100 cells. EDANS-positive cells, identified after removing 
background, were counted and compared to the total cell number counted by bright-field. 
Statistical Analysis. Significant differences between treatment groups were evaluated with an 
unpaired 
t-test with equal variance to calculate a two-tailed P-value. For the determination of IC50 values of 
proteasome inhibitors (i.e. the concentrations needed to halve the percentage of positive cells) the 
log 
concentration / % positive cells curves were fitted using the equation modeling a symmetrical 
sigmoid; 
this analysis enables to obtain the IC50 values with a 95% confidence interval. The significance of 
the 
difference among IC50 values was determined by the F-test. Data were analyzed using GraphPad 
Prism, version 5.03 software (GraphPad Software Inc.). 
Acknowledgements. This work was supported by grants from the Italian Ministry of Health and 
CARIPLO Foundation (533F/Q/1 and Guard, to M.S.) and from the Regione Piemonte (Progetti di 
Ricerca Sanitaria Finalizzata to P.C.). The kind gift of FMOC amino acids by Flamma S.p.A. 
(Bergamo, Italy) is gratefully acknowledged. The authors thank Laura Colombo and Alfredo 
Cagnotto 
for peptide synthesis, Chiara Milan and Alessandra Roncaglioni for mass spectrometric and 
molecular 
modeling studies. 
 
Supporting Information 
Additional Tables S1, S2 and Figures S1, S2, S3, S4, S5, S6, S7, S8 and S9 are described in the text. 
This material is available free of charge via the Internet at http://pubs.acs.org. 
References 
(1) Goldberg, A.L. Protein degradation and protection against misfolded or damaged proteins. 
Nature 2003, 426, 895-899. 
(2) Goldberg, A.L.; Cascio, P.; Saric, T.; Rock, K.L. The importance of the proteasome and 
subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 2002, 39, 
147-164. 
(3) Jung, T.; Catalgol, B.; Grune, T. The proteasomal system. Mol Aspects Med 2009, 30, 191-296. 
(4) Konstantinova, I.M.; Tsimokha, A.S.; Mittenberg, A.G. Role of proteasomes in cellular 
regulation. Int Rev Cell Mol Biol 2008, 267, 59-124. 
(5) Dahlmann, B. Role of proteasomes in disease. BMC Biochem 2007, 8 Suppl 1, S3. 
(6) Lehman, N.L. The ubiquitin proteasome system in neuropathology. Acta Neuropathol 2009, 
118, 329-347. 
(7) Burger, A.M.; Seth, A.K. The ubiquitin-mediated protein degradation pathway in cancer: 
therapeutic implications. Eur J Cancer 2004, 40, 2217-2229. 
 (8) Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5, 
417-421. 
(9) D'Alessandro, A.; Pieroni, L.; Ronci, M.; D'Aguanno, S.; Federici, G.; Urbani, A. Proteasome 
inhibitors therapeutic strategies for cancer. Recent Pat Anticancer Drug Discov 2009, 4, 73-82. 
(10) Voorhees, P.M.; Dees, E.C.; O'Neil, B.; Orlowski, R.Z. The proteasome as a target for cancer 
therapy. Clin Cancer Res 2003, 9, 6316-6325. 
(11) Curran, M.P.; McKeage, K. Bortezomib: a review of its use in patients with multiple myeloma. 
Drugs 2009, 69, 859-888. 
(12) Adams, J.; Palombella, V.J.; Sausville, E.A.; Johnson, J.; Destree, A.; Lazarus, D.D.; Maas, J.; 
Pien, C.S.; Prakash, S.; Elliott, P.J Proteasome inhibitors: a novel class of potent and effective 
antitumor agents. Cancer Res 1999, 59, 2615-2622. 
(13) Kisselev, A.F.; Goldberg, A.L. Monitoring activity and inhibition of 26S proteasomes with 
fluorogenic peptide substrates. Methods Enzymol 2005, 398, 364-378. 
(14) Dantuma, N.P.; Lindsten, K.; Glas, R.; Jellne, M.; Masucci, M.G. Short-lived green fluorescent 
proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat 
Biotechnol 2000, 18, 538-543. 
(15) Neefjes, J.; Dantuma, N.P. Fluorescent probes for proteolysis: tools for drug discovery. Nat 
Rev 
Drug Discov 2004, 3, 58-69. 
(16) Stack, J.H.; Whitney, M.; Rodems, S.M.; Pollok, B.A. A ubiquitin-based tagging system for 
controlled modulation of protein stability. Nat Biotechnol 2000, 18, 1298-1302. 
(17) Arendt, C.S.; Hochstrasser, M. Identification of the yeast 20S proteasome catalytic centers and 
subunit interactions required for active-site formation. Proc Natl Acad Sci U S A 1997, 94, 
7156-7161. 
 (18) Heinemeyer, W.; Fischer, M.; Krimmer, T.; Stachon, U.; Wolf, D.H. The active sites of the 
eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem 
1997, 272, 25200-25209. 
(19) Dolenc, I.; Seemuller, E.; Baumeister, W. Decelerated degradation of short peptides by the 20S 
proteasome. FEBS Lett 1998, 434, 357-361. 
(20) Derossi, D.; Calvet, S.; Trembleau, A.; Brunissen, A.; Chassaing, G.; and Prochiantz, A. Cell 
internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J 
Biol Chem 1996, 271, 18188-18193. 
(21) Jarver, P.; Langel, U. Cell-penetrating peptides--a brief introduction. Biochim Biophys Acta 
2006, 1758, 260-263. 
(22) Matayoshi, E.D.; Wang, G.T.; Krafft, G.A.; Erickson, J. Novel fluorogenic substrates for 
assaying retroviral proteases by resonance energy transfer. Science 1990, 247, 954-958. 
(23) Corey, M.J.; Hallakova, E.; Pugh, K.; Stewart, J.M. Studies on chymotrypsin-like catalysis by 
synthetic peptides. Appl Biochem Biotechnol 1994, 47, 199-210; discussion 210-212. 
(24) Fenteany, G.; Standaert, R.F.; Lane, W.S.; Choi, S.; Corey, E.J.; Schreiber S.L. Inhibition of 
proteasome activities and subunit-specific amino-terminal threonine modification by 
lactacystin. Science 1995, 268, 726-731. 
(25) Emmerich, N.P.; Nussbaum, A.K.; Stevanovic, S.; Priemer, M.; Toes, R.E.: Rammensee, H.G.; 
Schild, H. The human 26 S and 20 S proteasomes generate overlapping but different sets of 
peptide fragments from a model protein substrate. J Biol Chem 2000, 275, 21140-21148. 
(26) Holzhutter, H.G.; Frommel, C.; Kloetzel, P.M. A theoretical approach towards the 
identification 
of cleavage-determining amino acid motifs of the 20 S proteasome. J Mol Biol 1999, 286, 1251- 
1265. 
 (27) Frankel, A.D.; Pabo, C.O. Cellular uptake of the tat protein from human immunodeficiency 
virus. Cell 1988, 55, 1189-1193. 
(28) Herce, H.D.; Garcia, A.E. Molecular dynamics simulations suggest a mechanism for 
translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci U S A 
2007, 104, 20805-20810. 
(29) Hanada, M.; Sugawara, K.; Kaneta, K.; Toda, S.; Nishiyama, Y.; Tomita, K.; Yamamoto, H.; 
Konishi, M.; Oki, T. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo) 
1992, 45, 1746-1752. 
(30) Obeng, E.A.; Carlson, L.M.; Gutman, D.M.; Harrington, W.J. Jr; Lee, K.P.; Boise, L.H.. 
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. 
Blood 2006, 107, 4907-4916. 
(31) Craiu, A.; Gaczynska, M.; Akopian, T.; Gramm, C.F.; Fenteany, G.; Goldberg, A.L.; Rock, 
K.L. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits 
and inhibit intracellular protein degradation and major histocompatibility complex class I 
antigen presentation. J Biol Chem 1997, 272, 13437-13445. 
(32) Kisselev, A.F.; Goldberg, A.L. Proteasome inhibitors: from research tools to drug candidates. 
Chem Biol 2001, 8, 739-758. 
(33) Bianchi, G.; Oliva, L.; Cascio, P.; Pengo, N.; Fontana, F.; Cerruti, F.; Orsi, A.; Pasqualetto, E.; 
Mezghrani, A.; Calbi, V.; Palladini, G.; Giuliani, N.; Anderson, K.C.; Sitia, R.; Cenci, S. The 
proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma 
cells to proteasome inhibition. Blood 2009, 113, 3040-3049. 
 (34) Cascio, P.; Oliva, L.; Cerruti, F.; Mariani, E.; Pasqualetto, E.; Cenci, S.; Sitia R. Dampening 
Ab 
responses using proteasome inhibitors following in vivo B cell activation. Eur J Immunol 2008, 
38, 658-667. 
(35) Cenci, S.; Mezghrani, A.; Cascio, P.; Bianchi, G.; Cerruti, F.; Fra, A.; Lelouard, H.; 
Masciarelli, 
S.; Mattioli, L.; Oliva, L.; Orsi, A.; Pasqualetto, E.; Pierre, P.; Ruffato, E.; Tagliavacca, L.; 
Sitia, R. Progressively impaired proteasomal capacity during terminal plasma cell 
differentiation. EMBO J 2006, 25, 1104-1113. 
(36) Cenci, S.; Sitia, R. Managing and exploiting stress in the antibody factory. FEBS Lett 2007, 
581, 3652-3657. 
(37) Hanna, J.; Finley, D. A proteasome for all occasions. FEBS Lett 2007, 581, 2854-2861. 
(38) Cascio, P.; Hilton, C.; Kisselev, A.F.; Rock, K.L.; Goldberg, A.L. 26S proteasomes and 
immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO J 
2001, 20, 2357-2366. 
(39) Pandey, U.B.; Nie, Z.; Batlevi, Y.; McCray, BA.; Ritson, G.P.; Nedelsky, N.B.; Schwartz, 
S.L.; 
DiProspero, N.A.; Knight, M.A.; Schuldiner, O.; Padmanabhan, R.; Hild, M.; Berry, D.L.; 
Garza, D.; Hubbert, C.C.; Yao, T.P.; Baehrecke, E.H.; Taylor, J.P. HDAC6 rescues 
neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007, 
447, 859-863. 
(40) Menendez-Benito, V.; Heessen, S.; Dantuma, N.P. Monitoring of ubiquitin-dependent 
proteolysis with green fluorescent protein substrates. Methods Enzymol 2005, 399, 490-511. 
(41) Moravec, R.A.; O'Brien, M.A.; Daily, W.J.; Scurria, M.A.; Bernad, L.; Riss, T.L. Cell-based 
bioluminescent assays for all three proteasome activities in a homogeneous format. Anal 
Biochem 2009, 387, 294-302. 
 (42) Hara, T.; Nakamura, K.; Matsui, M.; Yamamoto, A.; Nakahara, Y.; Suzuki-Migishima, R.; 
Yokoyama, M.; Mishima, K.; Saito, I.; Okano, H.; and Mizushima, N. Suppression of basal 
autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441, 885-889. 
(43) Komatsu, M.; Waguri, S.; Chiba, T.; Murata, S.; Iwata, J.; Tanida, I.; Ueno, T.; Koike, M.; 
Uchiyama, Y.; Kominami, E.; Tanaka, K. Loss of autophagy in the central nervous system 
causes neurodegeneration in mice. Nature 2006, 441, 880-884. 
(44) Princiotta, M.F.; Finzi, D.; Qian, S.B.; Gibbs, J.; Schuchmann, S.; Buttgereit, F.; Bennink, J.R.; 
Yewdell, J.W. Quantitating protein synthesis, degradation, and endogenous antigen processing. 
Immunity 2003, 18, 343-354. 
(45) Richard, J.P.; Melikov, K.; Vives, E.; Ramos, C.; Verbeure, B.; Gait, M.J.; Chernomordik, 
L.V.; Lebleu, B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. 
J Biol Chem 2003, 278, 585-590. 
(46) Cascio, P.; Goldberg, A.L. Preparation of hybrid (19S-20S-PA28) proteasome complexes and 
analysis of peptides generated during protein degradation. Methods Enzymol 2005, 398, 336- 
352. 
(47) Kony, D.B.; Hunenberger, P.H.; van Gunsteren, W.F. Molecular dynamics simulations of the 
native and partially folded states of ubiquitin: influence of methanol cosolvent, pH, and 
temperature on the protein structure and dynamics. Protein Sci 2007, 16, 1101-1118. 
(48) Rocchia, W.; Sridharan, S.; Nicholls, A.; Alexov, E.; Chiabrera, A.; Honig, B. Rapid grid-
based 
construction of the molecular surface and the use of induced surface charge to calculate reaction 
field energies: applications to the molecular systems and geometric objects. J Comput Chem 
2002, 23, 128-137. 
 (49) Repici, M.; Mare, L.; Colombo, A.; Ploia, C.; Sclip, A.; Bonny, C.; Nicod, P.; Salmona, M.; 
Borsello, T. c-Jun N-terminal kinase binding domain-dependent phosphorylation of 
mitogenactivated 
protein kinase kinase 4 and mitogen-activated protein kinase kinase 7 and balancing 
cross-talk between c-Jun N-terminal kinase and extracellular signal-regulated kinase pathways 
in cortical neurons. Neuroscience 2009, 159, 94-103. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Percentage of Fluorescent Positive Cells after TED Treatment, with or without 
Epoxomicin. 
 
      
 
 
Cells were incubated for 15 min with 17 µM TED, in the presence or absence of 5 µM of the 
proteasome inhibitor epoxomicin. The number of positive cells is expressed as percentage of total 
cells. 
Data are mean ± standard error of the mean (SEM) of three independent experiments, each 
performed 
with at least 100 cells; * P < 0.05; ** P < 0.01; *** P < 0.001, unpaired t-test. 
 
 
 
Figure Legends 
Figure 1. Schematic Structure of TED. Primary amino acid sequence, showing linkage of 
fluorophores 
DABCYL and EDANS to Lys 2 and Glu 10, respectively. The blue arrow indicates the preferred 
cleavage site, yellow arrows the secondary primed regions and red dashed arrows the non-primed 
regions. Residues 48-57 of the TAT protein were linked to the side chain of Glu 10 at the C-
terminus. 
D-amino acids are in position 1,3,4. 
Figure 2. Mass Spectrometric Analysis of TED Degradation Products. HeLa cells were incubated 
with 
17 µM TED for 15 min at 37 °C and cell lysates were analyzed by MALDI-TOF MS. (A) The 
molecular ion at m/z 3084.48 corresponds to uncleaved TED [M+H]+. (B) The molecular ion at m/z 
1270.97 corresponds to cleavage of TED at the carboxyl end of the Tyr at position 8. The molecular 
ion 
at m/z 1141.58 corresponds to TED cleavage both at the Tyr residue and the N-terminal Lys residue 
and the molecular ion at m/z 2046.43 corresponds to the peptide from cleavage between the two 
Lys at 
positions 13 and 14 in the TAT sequence. Uncleaved TED molecular ion [M+H]+ was negligible at 
m/z 
3084.97. 
Figure 3. TED Internalization and Cleavage in U266 Cells. (A) Representative micrographs 
showing 
progressive TED internalization and cleavage after 0, 5 and 15 min incubation with 17 µM TED. 
Peptide cleavage resulted in significant EDANS fluorescence increase, monitored by time-lapse 
recording microscopy. Pre-incubation for 3 h with 5 µM of the proteasome inhibitor epoxomicin, 
followed by co-incubation with TED for 15 min, significantly prevented EDANS fluorescence. 
Scale 
bar: 50 µm. (B) Quantification of fluorescence-positive U266 cells after 15 min incubation with 
TED. 
Treatment with epoxomicin significantly reduced the number of positive cells; ** P < 0.01, 
unpaired t-test. Data are mean ± standard error of the mean (SEM) from three independent 
experiments. (C) Flowcytometry 
of EDANS and GFP fluorescence in UbG76VGFP-U266 cells incubated with 17 µM TED for 
15 min, in the presence or absence of 5 µM epoxomicin. Incubation with TED alone resulted in 
increased EDANS mean fluorescence intensity (MFI), which was partially prevented by pre-
treatment 
with epoxomicin; no fluorescence was detected in untreated cells (CTR). GFP fluorescence was 
barely 
detectable in untreated cells (CTR), but accumulated upon pre-treatment with epoxomicin. 
Figure 4. Dose-Response Curves of TED Cleavage Inhibition. HeLa cells were pre-incubated for 3 
h 
with different concentrations of epoxomicin (Epox from 0.5 to 20 µM), MG-132 (from 1 to 20 µM) 
or 
bortezomib (BTZ from 0.01 to 1 µM), and then treated with 17 µM TED for 15 min. Quantification 
of 
fluorescence-positive cells was carried out at each inhibitor concentration on 50-70 cells from 8-10 
images. The IC50 of the inhibitors were 13.08 µM for epoxomicin, 6.45 µM for MG-132 and 141.3 
nM 
for bortezomib (p=0.0016, F=14.26). Results are expressed as mean ± standard error of the mean 
(SEM) from two independent experiments. 
Figure 5. Intracellular Distribution of TED in Primary Hippocampal Neurons and U266 Multiple 
Myeloma Cells. (A) Cells were pre-incubated for 5 min at 37 °C with 1 µM SYTO59 to stain cell 
nuclei, followed by 15 min incubation with 17 µM TED. EDANS fluorescence was monitored by 
timelapse 
recording microscopy. EDANS, green; SYTO59, red; co-localization of TED and SYTO59 is 
shown by merged micrographs (third column). Scale bar: 20 µm. (B) Pseudocolor images with 
localization of TED in the nucleus of hippocampal neurons, as indicated by a color shift from blue 
to 
red, with a more homogeneous distribution in U266 cells. Micrographs showing intracellular 
localization of TED and pseudocolor images for different cell lines are in Figure S8. 
Figure 6. Time-course of TED Cleavage Efficiency in MM.1S and U266 Multiple Myeloma Cell 
Lines. Cells were incubated with 17 µM TED for 30 min and EDANS fluorescence changes 
monitored 
by flow cytometry for 30 min. Data were acquired every 3 min. Mean fluorescence intensity (MFI) 
progressively increased over incubation, with lower values in MM.1S than U266 cells at every time 
point. Two representative time points are shown. The number of positive cells/channel was also 
lower 
in MM.1S than U266 cells. Data are from one representative experiment of two. 
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